Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GJB2 | P29033 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | MTAP | Q13126 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580825 | 1.00 | BCHE (0.49) | BCHEACHEPDPK1MTORPDE4D | |
| SCHEMBL14583809 | 1.00 | BCHE (0.49) | BCHEACHEPDPK1MTORPDE4D | |
| SCHEMBL13562761 | 1.00 | BCHE (0.49) | BCHEACHEPDPK1MTORPDE4D | |
| SCHEMBL13424410 | 1.00 | BCHE (0.49) | BCHEACHEPDPK1MTORPDE4D | |
| SCHEMBL12152898 | 1.00 | BCHE (0.49) | BCHEACHEPDPK1MTORPDE4D | |
| SCHEMBL21783270 | 1.00 | BCHE (0.49) | BCHEACHEPDPK1MTORPDE4D | |
| SCHEMBL2637305 | 0.87 | BCHE (0.46) | BCHEACHEPDPK1MTORPDE4D | |
| SCHEMBL14697116 | 0.87 | BCHE (0.46) | BCHEACHEPDPK1MTORPDE4D | |
| SCHEMBL2637306 | 0.87 | BCHE (0.46) | BCHEACHEPDPK1MTORPDE4D | |
| SCHEMBL2638079 | 0.87 | BCHE (0.46) | BCHEACHEPDPK1MTORPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | BCHE 2092/4885ACHE 3563/4885PDPK1 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.